Business Context and Reporting Period
This Form 8-K Current Report was filed by Revelation Biosciences, Inc. on June 12, 2023. The filing serves as a Regulation FD disclosure regarding the outcome of the Company's Annual Meeting of Stockholders held on June 9, 2023.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a procedural report regarding corporate governance events.
Material Changes
- Annual Meeting Adjournment: The Annual Meeting of Stockholders held on June 9, 2023, was adjourned to July 7, 2023 because a quorum was not present.
- New Proposal: An additional proposal was added to the agenda for the rescheduled meeting to ratify Baker Tilly US, LLP as the Company's independent auditors for the fiscal year ending December 31, 2023.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of operational risks. The primary contingency noted is the rescheduling of the shareholder vote due to insufficient attendance.
Key Facts for Investor Verification
- Verify the date and agenda for the rescheduled Annual Meeting on July 7, 2023.
- Confirm the status of the auditor ratification proposal for Baker Tilly US, LLP.
- Note that the information in this filing is deemed "furnished" and not "filed" for purposes of Section 18 of the Exchange Act.